
## Rubén Dario Sinisterra MillÃ;n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1271722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alamandine Induces Neuroprotection in Ischemic Stroke Models. Current Medicinal Chemistry, 2022, 29, 3483-3498.	2.4	2
2	Impact of DMPEI on Biofilm Adhesion on Latex Urinary Catheter. Recent Patents on Biotechnology, 2021, 15, 51-66.	0.8	1
3	Sulfonamide-Functionalized Polymeric Nanoparticles For Enhanced In Vivo Colorectal Cancer Therapy. Current Drug Delivery, 2021, 18, .	1.6	0
4	Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells. PeerJ, 2021, 9, e12124.	2.0	9
5	Versatile grafted microcrystalline cellulose with ionic liquid as new Losartan-controlled release material. European Polymer Journal, 2020, 124, 109490.	5.4	8
6	Long-term colloidal stability of graphene oxide aqueous nanofluids. Fullerenes Nanotubes and Carbon Nanostructures, 2020, 28, 407-417.	2.1	17
7	Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. Journal of Proteomics, 2019, 208, 103486.	2.4	13
8	Polycaprolactone nanofibers loaded oxytetracycline hydrochloride and zinc oxide for treatment of periodontal disease. Materials Science and Engineering C, 2019, 103, 109798.	7.3	49
9	Guaiacol/β-cyclodextrin for rapid healing of dry socket: antibacterial activity, cytotoxicity, and bone repair—an animal study. Oral and Maxillofacial Surgery, 2019, 23, 53-61.	1.3	3
10	Testosterone improves the osteogenic potential of a composite in vitro and in vivo. Cell and Tissue Research, 2019, 376, 221-231.	2.9	4
11	A long-lasting oral preformulation of the angiotensin II AT1 receptor antagonist losartan. Drug Development and Industrial Pharmacy, 2018, 44, 1498-1505.	2.0	9
12	Neuroprotection by postâ€stroke administration of an oral formulation of angiotensinâ€(1–7) in ischaemic stroke. Experimental Physiology, 2018, 103, 916-923.	2.0	29
13	Hybrid nanofibers based on poly-caprolactone/gelatin/hydroxyapatite nanoparticles-loaded Doxycycline: Effective anti-tumoral and antibacterial activity. Materials Science and Engineering C, 2018, 83, 25-34.	7.3	81
14	Eccentric Overload Muscle Damage is Attenuated By a Novel Angiotensin- (1-7) Treatment. International Journal of Sports Medicine, 2018, 39, 743-748.	1.7	21
15	Evidence of hypoglycemic, lipid-lowering and hepatoprotective effects of the Bixin and Bixin: β-CD inclusion compound in high-fat-fed obese mice. Biomedicine and Pharmacotherapy, 2018, 106, 363-372.	5.6	28
16	Efficient cutaneous wound healing using bixin-loaded PCL nanofibers in diabetic mice. , 2017, 105, 1938-1949.		46
17	Magnetic nanoparticles coated with cyclodextrins and citrate for irinotecan delivery. Carbohydrate Polymers, 2017, 163, 1-9.	10.2	46
18	Sub-additive effects of photodynamic therapy combined with erlotinib for the treatment of epidermoid carcinoma: An in vitro study. Photodiagnosis and Photodynamic Therapy, 2017, 18, 252-256.	2.6	5

#	Article	IF	CITATIONS
19	Antibacterial Effect of Synthetic Peptide LyeTxI and LyeTxI/β-Cyclodextrin Association Compound Against Planktonic and Multispecies Biofilms of Periodontal Pathogens. Journal of Periodontology, 2017, 88, e88-e96.	3.4	13
20	Efficient antibacterial nanosponges based on ZnO nanoparticles and doxycycline. Journal of Photochemistry and Photobiology B: Biology, 2017, 177, 85-94.	3.8	13
21	Nanofibers containing tetracycline/β-cyclodextrin: Physico-chemical characterization and antimicrobial evaluation. Carbohydrate Polymers, 2017, 156, 417-426.	10.2	37
22	Antidiarrheal activity of extracts from Maytenus gonoclada and inhibition of Dengue virus by lupeol. Anais Da Academia Brasileira De Ciencias, 2017, 89, 1555-1564.	0.8	12
23	KR12 peptide associated with cyclodextrin: Antimicrobial and antitumor activities. Biointerphases, 2016, 11, 04B307.	1.6	5
24	Therapeutic uses for Angiotensin-(1-7). Expert Opinion on Therapeutic Patents, 2016, 26, 669-678.	5.0	25
25	Osteogenic activity of cyclodextrin-encapsulated doxycycline in a calcium phosphate PCL and PLGA composite. Materials Science and Engineering C, 2016, 64, 370-375.	7.3	20
26	Erlotinib/hydroxypropyl-β-cyclodextrin inclusion complex: characterization and in vitro and in vivo evaluation. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2015, 83, 267-279.	1.6	14
27	Development of Sulfadiazine-Decorated PLGA Nanoparticles Loaded with 5-Fluorouracil and Cell Viability. Molecules, 2015, 20, 879-899.	3.8	21
28	Electrospun nanofibers of polyCD/PMAA polymers and their potential application as drug delivery system. Materials Science and Engineering C, 2015, 54, 252-261.	7.3	51
29	Cyclodextrin modulates the cytotoxic effects of chlorhexidine on microrganisms and cells <i>in vitro</i> . Drug Delivery, 2015, 22, 444-453.	5.7	17
30	PLGA nanofibers improves the antitumoral effect of daunorubicin. Colloids and Surfaces B: Biointerfaces, 2015, 136, 248-255.	5.0	33
31	New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape. Expert Opinion on Therapeutic Patents, 2015, 25, 247-260.	5.0	31
32	TECHNOLOGICAL INFORMATION SEARCHING BASED ON PATENT DATABANK: CASE STUDY OF IONIC LIQUIDS IN BRAZIL. Quimica Nova, 2015, , .	0.3	3
33	Chronic oral administration of Ang-(1–7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. Clinical Science, 2014, 127, 101-109.	4.3	34
34	Efficacy of coral-hydroxyapatite and biphasic calcium phosphate for early bacterial detection. Biointerphases, 2014, 9, 029018.	1.6	4
35	Structural and thermodynamic characterization of doxycycline/β-cyclodextrin supramolecular complex and its bacterial membrane interactions. Colloids and Surfaces B: Biointerfaces, 2014, 118, 194-201.	5.0	39
36	Proteomic white adipose tissue analysis of obese mice fed with a high-fat diet and treated with oral angiotensin-(1–7). Peptides, 2014, 60, 56-62.	2.4	23

#	Article	IF	CITATIONS
37	Cross talk between angiotensin-(1–7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice. Peptides, 2014, 55, 158-165.	2.4	68
38	Treatment with Angiotensin-(1–7) reduces inflammation in carotid atherosclerotic plaques. Thrombosis and Haemostasis, 2014, 111, 736-747.	3.4	47
39	Development of a Calcium Phosphate Nanocomposite for Fast Fluorogenic Detection of Bacteria. Molecules, 2014, 19, 13948-13964.	3.8	5
40	Oral Angiotensin-(1–7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with high-fat diet. Peptides, 2013, 46, 47-52.	2.4	114
41	An Oral Formulation of Angiotensin-(1-7) Reverses Corpus Cavernosum Damages Induced by Hypercholesterolemia. Journal of Sexual Medicine, 2013, 10, 2430-2442.	0.6	34
42	Peptides: β-Cyclodextrin Inclusion Compounds as Highly Effective Antimicrobial and Anti-Epithelial Proliferation Agents. Journal of Periodontology, 2013, 84, 1858-1868.	3.4	14
43	Optimized dispersion of ZnO nanoparticles and antimicrobial activity against foodborne pathogens and spoilage microorganisms. Journal of Nanoparticle Research, 2013, 15, 1.	1.9	22
44	Control of size in losartan/copper(II) coordination complex hydrophobic precipitate. Materials Science and Engineering C, 2013, 33, 3916-3922.	7.3	10
45	Multiple complexation of cyclodextrin with soy isoflavones present in an enriched fraction. Carbohydrate Polymers, 2013, 98, 726-735.	10.2	35
46	Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market. Journal of Chemical Biology, 2013, 6, 7-23.	2.2	23
47	Evaluation of antimicrobial activity and cell viability of Aloe vera sponges. Electronic Journal of Biotechnology, 2013, 16, .	2.2	5
48	Double continuous injection preparation method of cyclodextrin inclusion compounds by spray drying. Chemical Engineering Journal, 2013, 228, 345-351.	12.7	15
49	Ultrastructural changes in bacterial membranes induced by nano-assemblies β-cyclodextrin chlorhexidine: SEM, AFM, and TEM evaluation. Pharmaceutical Development and Technology, 2013, 18, 600-608.	2.4	16
50	Oral Formulation of Angiotensin-(1–7) Improves Lipid Metabolism and Prevents High-Fat Diet–Induced Hepatic Steatosis and Inflammation in Mice. Hypertension, 2013, 62, 324-330.	2.7	84
51	Discovery and Characterization of Alamandine. Circulation Research, 2013, 112, 1104-1111.	4.5	323
52	Panorama de propriedade intelectual, transferência de tecnologia e inovação da quÃmica brasileira e a comparação com os paÃses do BRIC. Quimica Nova, 2013, 36, 1527-1532.	0.3	3
53	Chlorhexidine/losartan ionic pair binding and its nanoprecipitation: physico-chemical characterisation and antimicrobial activity. Supramolecular Chemistry, 2012, 24, 204-212.	1.2	15
54	Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats. International Journal of Hypertension, 2012, 2012, 1-12.	1.3	55

#	Article	IF	CITATIONS
55	Insights into the multi-equilibrium, superstructure system based on β-cyclodextrin and a highly water soluble guest. International Journal of Pharmaceutics, 2012, 439, 207-215.	5.2	15
56	In vivo evaluation of the highly soluble oral β-cyclodextrin–Sertraline supramolecular complexes. International Journal of Pharmaceutics, 2012, 436, 478-485.	5.2	18
57	Superstructure based on $\hat{l}^2$ -CD self-assembly induced by a small guest molecule. Physical Chemistry Chemical Physics, 2012, 14, 1934.	2.8	41
58	Effect of testosterone incorporation on cell proliferation and differentiation for polymer–bioceramic composites. Journal of Materials Science: Materials in Medicine, 2012, 23, 2751-2759.	3.6	6
59	A biodegradable porous composite scaffold of PCL/BCP containing Ang-(1-7) for bone tissue engineering. Ceramica, 2012, 58, 481-488.	0.8	18
60	Desmistificando a proteção por patentes nas universidades. Quimica Nova, 2012, 35, 1700-1705.	0.3	2
61	Preparação do composto de associação entre citrato de ródio(II) e β-ciclodextrina. Quimica Nova, 2012, 35, 762-765.	0.3	4
62	Self-assembled organic–inorganic magnetic hybrid adsorbent ferrite based on cyclodextrin nanoparticles. Beilstein Journal of Organic Chemistry, 2012, 8, 1867-1876.	2.2	6
63	Chlorhexidine: beta-cyclodextrin inhibits yeast growth by extraction of ergosterol. Brazilian Journal of Microbiology, 2012, 43, 810-818.	2.0	9
64	In vitro and in vivo evaluation of the biocompatibility of a calcium phosphate/poly(lactic-co-glycolic) Tj ETQq0 0 C	rgBT /Ove	erlock 10 Tf 5
65	Interaction between bradykinin potentiating nonapeptide (BPP9a) and β-cyclodextrin: A structural and thermodynamic study. Materials Science and Engineering C, 2012, 32, 244-253.	7.3	9
66	An Oral Formulation of Angiotensin-(1-7) Produces Cardioprotective Effects in Infarcted and Isoproterenol-Treated Rats. Hypertension, 2011, 57, 477-483.	2.7	124
67	Daidzein/cyclodextrin/hydrophilic polymer ternary systems. Drug Development and Industrial Pharmacy, 2011, 37, 886-893.	2.0	39
68	Pharmaceutical Composition of Hydrochlorothiazide:β-Cyclo-dextrin: Preparation by Three Different Methods, Physico-Chemical Characterization and In Vivo Diuretic Activity Evaluation. Molecules, 2011, 16, 4482-4499.	3.8	36
69	Study of the BPP7a peptide and its β-cyclodextrin complex: physicochemical characterization and complete sequence specific NMR assignments. Journal of the Brazilian Chemical Society, 2011, 22, 1765-1773.	0.6	7
70	Multi-equilibrium system based on sertraline and β-cyclodextrin supramolecular complex in aqueous solution. International Journal of Pharmaceutics, 2011, 421, 24-33.	5.2	47
71	Preparation and characterization of poly(l,l-lactide)-b-poly(ethylene glycol)-b-poly(l,l-lactide) (PLLA-PEG-PLLA) microspheres having encapsulated tetracycline. Journal of Thermal Analysis and Calorimetry, 2011, 106, 671-677.	3.6	7
72	Inhibition of Candida albicans CC biofilms formation in polystyrene plate surfaces by biosurfactant produced by Trichosporon montevideense CLOA72. Colloids and Surfaces B: Biointerfaces, 2011, 84, 467-476.	5.0	32

#	Article	IF	CITATIONS
73	Supramolecular interactions between losartan and hydroxypropyl-β-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. International Journal of Pharmaceutics, 2011, 404, 116-123.	5.2	43
74	An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics, 2011, 66, 837-841.	1.5	89
75	A new controlled release system of chlorhexidine and chlorhexidine:βcd inclusion compounds based on porous silica. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2010, 67, 159-168.	1.6	21
76	Structural and physical–chemical evaluation of Bradykinin Potentiating Peptide and its high soluble supramolecular complex. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2010, 67, 407-422.	1.6	17
77	New insights regarding the cyclodextrin/AAS self-assembly: A molar ratio dependent system. Materials Science and Engineering C, 2010, 30, 417-422.	7.3	10
78	Bioceramic/Poly (glycolic)-poly (lactic acid) composite induces mineralized barrier after direct capping of rat tooth pulp tissue. Brazilian Oral Research, 2010, 24, 08-14.	1.4	10
79	Improvement of genistein content in solid genistein/-cyclodextrin complexes β. Quimica Nova, 2010, 33, 587-590.	0.3	15
80	Pharmaceutical Composition of Valsartan: β-Cyclodextrin: Physico–Chemical Characterization and Anti-Hypertensive Evaluation. Molecules, 2010, 15, 4067-4084.	3.8	44
81	Photo-response behavior of electrospun nanofibers based on spiropyran-cyclodextrin modified polymer. Journal of Materials Chemistry, 2010, 20, 9910.	6.7	61
82	Benzaldehyde semicarbazone: a drug candidate that associates structural simplicity to a wide range of activities. Revista Virtual De Quimica, 2010, 2, .	0.4	1
83	Inclusion complex of usnic acid with β-cyclodextrin: characterization and nanoencapsulation into liposomes. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2009, 64, 215-224.	1.6	67
84	Complexation with β-cyclodextrin confers oral activity on the flavonoid dioclein. International Journal of Pharmaceutics, 2009, 367, 133-139.	5.2	36
85	Studies on coumestrol/β-cyclodextrin association: Inclusion complex characterization. International Journal of Pharmaceutics, 2009, 369, 5-11.	5.2	41
86	Quercetin/β-Cyclodextrin Solid Complexes Prepared in Aqueous Solution Followed by Spray-drying or by Physical Mixture. AAPS PharmSciTech, 2009, 10, 235-242.	3.3	78
87	Association of 3-O-methylquercetin with β-cyclodextrin: complex preparation, characterization and exÂvivo skin permeation studies. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2008, 62, 149-159.	1.6	17
88	Study of inclusion compound in solution involving tetracycline and β-cyclodextrin by FTIR-ATR. Vibrational Spectroscopy, 2008, 46, 57-62.	2.2	39
89	Supramolecular complex of fluoxetine with β-cyclodextrin: An experimental and theoretical study. International Journal of Pharmaceutics, 2008, 353, 160-169.	5.2	56
90	Supramolecular Self-Assembly of Cyclodextrin and Higher Water Soluble Guest: Thermodynamics and Topological Studies. Journal of the American Chemical Society, 2008, 130, 8426-8436.	13.7	79

#	Article	IF	CITATIONS
91	Study of angiotensin-(1–7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides, 2007, 28, 2199-2210.	2.4	104
92	Supramolecular self-assembly of β-cyclodextrin: an effective carrier of the antimicrobial agent chlorhexidine. Carbohydrate Research, 2007, 342, 2286-2296.	2.3	84
93	Polymer: Bioceramic composites optimization by tetracycline addition. International Journal of Pharmaceutics, 2007, 336, 75-81.	5.2	14
94	Novel pharmaceutical composition of bradykinin potentiating penta peptide with β-cyclodextrin: Physical–chemical characterization and anti-hypertensive evaluation. International Journal of Pharmaceutics, 2007, 336, 90-98.	5.2	29
95	A Supramolecular Complex between Proteinases and ??-Cyclodextrin that Preserves Enzymatic Activity. BioDrugs, 2006, 20, 283-291.	4.6	35
96	Mode of action of β-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. International Journal of Pharmaceutics, 2006, 325, 39-47.	5.2	37
97	An Inclusion Compound of the Anticonvulsant Sodium Valproate into α-Cyclodextrin: Physico-Chemical Characterization. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2006, 54, 133-138.	1.6	18
98	Self-assembly Characterization of the β-Cyclodextrin and Hydrochlorothiazide System: NMR, Phase Solubility, ITC and QELS. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2006, 55, 41-49.	1.6	33
99	Spironolactone and its Complexes with β-cyclodextrin: Modern NMR Characterization and Structural DFTB-SCC Calculations. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2006, 56, 293-302.	1.6	12
100	Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with β-cyclodextrin. Biomaterials, 2004, 25, 327-333.	11.4	111
101	An Alternative Approach Based on Artificial Neural Networks to Study Controlled Drug Release. Journal of Pharmaceutical Sciences, 2004, 93, 418-430.	3.3	25
102	A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterials, 2004, 25, 3743-3750.	11.4	118
103	Preparation of ferrofluid from cyclodextrin and magnetite. Journal of Magnetism and Magnetic Materials, 2004, 272-276, 2395-2397.	2.3	19
104	Association complexes between ovalbumin and cyclodextrins have no effect on the immunological properties of ovalbumin. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 199-205.	4.3	26
105	Oral Delivery of Meglumine Antimoniate-β-Cyclodextrin Complex for Treatment of Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2004, 48, 100-103.	3.2	80
106	Inclusion of Benzaldehyde Semicarbazone intoβ-Cyclodextrin Produces a Very Effective Anticonvulsant Formulation. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2003, 47, 77-82.	1.6	18
107	Surface effects and desorption of tetracycline supramolecular complex on bovine dentine. Biomaterials, 2003, 24, 1075-1080.	11.4	15
108	In Vitro Effects of a Chlorhexidine Controlled Delivery System. Artificial Organs, 2003, 27, 486-491.	1.9	18

#	Article	IF	CITATIONS
109	Preparation of a ferrofluid using cyclodextrin and magnetite. Journal of the Brazilian Chemical Society, 2003, 14, 936-941.	0.6	44
110	An effective anticonvulsant prepared following a host–guest strategy that uses hydroxypropyl-β-cyclodextrin and benzaldehyde semicarbazone. Biochemical and Biophysical Research Communications, 2002, 296, 241-246.	2.1	31
111	Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. Biomaterials, 2002, 23, 2519-2526.	11.4	35
112	Complex Material Using β-Cyclodextrins and Nickel-Zinc Ferrite to Obtain a Magnetically Targetable Drug Carrier. Materials Research Society Symposia Proceedings, 2001, 711, 1.	0.1	1
113	Positronium formation in lanthanide (III) trifluoroacetate with 3-picoline-N-oxide compounds. Chemical Physics Letters, 2001, 333, 371-374.	2.6	17
114	Title is missing!. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2001, 40, 297-302.	1.6	62
115	?-Cyclodextrin and methylmercury chloride: a new strategy to recover organomercurials. Applied Organometallic Chemistry, 2000, 14, 507-513.	3.5	3
116	Quantum-mechanical study of the interaction of α-cyclodextrin with methyl mercury chloride. Chemical Physics Letters, 2000, 319, 569-575.	2.6	41
117	Spectroscopic study of the inclusion compound of β-cyclodextrin and Tris(dibenzoylmethane)europium(III) dihydrate. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 1999, 55, 2403-2410.	3.9	31
118	Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-β-cyclodextrin from biodegradable polymer microspheres. Journal of Pharmaceutical Sciences, 1999, 88, 574-576.	3.3	29
119	Title is missing!. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 1999, 33, 203-216.	1.6	3
120	Thermal behaviour and isothermal kinetics of rhodium(II) acetate. Thermochimica Acta, 1997, 296, 141-148.	2.7	8
121	Positron Annihilation Studies on Reactor Irradiated and Thermal Annealed Ferrocene. Radiochimica Acta, 1996, 73, 95-100.	1.2	2
122	The inclusion of rhodium(II)?-methyl-cinnamate in ?-cyclodextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 1995, 22, 91-98.	1.6	15
123	Synthesis and Spectroscopic Studies on Dirhodium (II) Carboxylate Adducts with Sulfadiazine. Spectroscopy Letters, 1993, 26, 245-259.	1.0	4
124	A Raman Spectroscopic Investigation of Sulphadiazine and of Its Dirhodium Tetracarboxylate Adducts. Spectroscopy Letters, 1993, 26, 305-318.	1.0	5